SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+0.89%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.06B
AUM Growth
+$1.06B
(+0%)
Cap. Flow
+$72.8M
Cap. Flow
% of AUM
6.9%
Top 10 Holdings %
Top 10 Hldgs %
58.8%
Holding
82
New
15
Increased
23
Reduced
6
Closed
12
Top Buys
| 1 |
Amgen
AMGN
|
$17.9M |
| 2 |
United Therapeutics
UTHR
|
$15.5M |
| 3 |
Bristol-Myers Squibb
BMY
|
$15.4M |
| 4 |
Pfizer
PFE
|
$14.8M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$12.1M |
Top Sells
| 1 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
$17.5M |
| 2 |
Novo Nordisk
NVO
|
$16.5M |
| 3 |
Heron Therapeutics
HRTX
|
$9.5M |
| 4 |
Incyte
INCY
|
$5.91M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$4.16M |
Sector Composition
| 1 | Healthcare | 91.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $107M | 9.67% | 1,109,874 +10,050 | +0.9% | +$968K |
|
2
Natera
NTRA
$23.1B
| $102M | 9.2% | 3,100,560 | – | – |
|
|
AMRN
3
Amarin Corp
AMRN
$311M
| $79M | 7.14% | 5,208,305 | – | – |
|
4
NextCure
NXTC
$13.5M
| $77.8M | 7.03% | 2,521,856 | – | – |
|
5
Y-mAbs Therapeutics
YMAB
$388M
| $54.8M | 4.96% | 2,104,278 | – | – |
|
|
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $46.7M | 4.22% | 481,270 | – | – |
|
|
PRNB
7
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $40M | 3.62% | 1,417,258 -620,950 | -30% | -$17.5M |
|
|
OBSV
8
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $39.6M | 3.58% | 4,749,623 | – | – |
|
9
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $39.2M | 3.54% | 1,933,221 -160,000 | -8% | -$3.24M |
|
10
Merus
MRUS
$4.98B
| $34.9M | 3.16% | 1,961,039 | – | – |
|
|
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $28.2M | 2.55% | 1,729,352 | – | – |
|
|
BOLD
12
DELISTED
Audentes Therapeutics, Inc
BOLD
| $26.2M | 2.37% | 933,640 | – | – |
|
|
13
Bristol-Myers Squibb
BMY
$96B
| $24.3M | 2.19% | 478,349 +304,500 | +175% | +$15.4M |
|
|
AGN
14
DELISTED
Allergan plc
AGN
| $22.6M | 2.05% | 134,433 +50,000 | +59% | +$8.41M |
|
|
15
Vertex Pharmaceuticals
VRTX
$100B
| $20.6M | 1.86% | 121,690 +71,389 | +142% | +$12.1M |
|
|
16
Amgen
AMGN
$155B
| $17.9M | 1.61% | +92,300 | New | +$17.9M |
|
17
Neurocrine Biosciences
NBIX
$13.8B
| $17.3M | 1.56% | 191,679 +35,819 | +23% | +$3.23M |
|
|
NCNA
18
NuCana
NCNA
$6.09M
| $16.4M | 1.48% | 2,266,666 | – | – |
|
|
XLRN
19
DELISTED
Acceleron Pharma Inc.
XLRN
| $16.1M | 1.46% | 408,262 +167,219 | +69% | +$6.61M |
|
|
20
United Therapeutics
UTHR
$13.8B
| $15.5M | 1.4% | +194,014 | New | +$15.5M |
|
|
21
Pfizer
PFE
$141B
| $14.8M | 1.33% | +410,607 | New | +$14.8M |
|
|
RETA
22
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $11.9M | 1.08% | 148,669 +33,133 | +29% | +$2.66M |
|
23
Iterum Therapeutics
ITRM
$30.2M
| $9.96M | 0.9% | 1,726,514 | – | – |
|
24
Halozyme
HALO
$8.56B
| $9.87M | 0.89% | 636,167 -54,032 | -8% | -$838K |
|
25
TG Therapeutics
TGTX
$4.65B
| $9.73M | 0.88% | 1,733,628 +472,244 | +37% | +$2.65M |
|